Here are four things to know.
1. Baxter first recalled one lot of Nexterone Nov. 10 due to the presence of particulate matter. The drugmaker has since expanded the recall to include a second lot of the drug.
2. The particulate matter was consistent with polyethylene, the primary ingredient of the film and ports used to manufacture the bag for Nexterone.
3. Baxter distributed the affected lots to wholesalers and healthcare facilities nationwide between July 21 and Oct. 2.
4. Administering an intravenous drug with sterile particulate matter to patients could cause adverse health effects, although Baxter has not received any reports of adverse events to date.
More articles on supply chain:
Mylan reaffirms $1B share buyback plan
FDA: IV fluid shortage exacerbated by hurricane damage to Puerto Rico is expected to improve
Stanford Blood Center faces critical shortage of blood, notes the flu is keeping potential donors away
